Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up FDA? CDRH Seeks Entrepreneurial Spirit With New “In-Residence” Program

This article was originally published in The Gray Sheet

Executive Summary

CDRH is hoping to inject a dose of start-up-firm mentality into its processes with the official launch last week of the entrepreneurs-in-residence pilot program as part of a broader FDA push to highlight its “innovation” bona fides.

You may also be interested in...



New Metrics For Clinical Trial Oversight Floated By CDRH Entrepreneurs In Residence

Variability runs high in FDA’s process for approving new device trials, but the agency is open to recommendations for improvements coming out of its entrepreneurs-in-residence program, says Chip Hance, a former Abbott executive participating in the program.

CDRH Entrepreneurs Take Two: Streamlining Data Collection And The Path To Reimbursement

FDA’s device center launched the second round of its entrepreneurs-in-residence program, bringing in outside experts to the center to focus on streamlining data collection and the approval-to-reimbursement pathway.

CDRH Accelerates Software Development To Improve Collaboration With Industry

FDA’s device center hopes the effort, which is intended to model a quicker-turnaround “Silicon Valley” approach to system development, will help reduce time-to-market for new devices, and simplify some post-market surveillance efforts.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030625

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel